Ignite Creation Date:
2024-05-06 @ 6:12 PM
Last Modification Date:
2024-10-26 @ 2:43 PM
Study NCT ID:
NCT05573217
Status:
UNKNOWN
Last Update Posted:
2022-10-10
First Post:
2022-10-03
Brief Title:
The Utility of Cell-free DNA Methylation Markers for Hepatocellular Carcinoma
Sponsor:
National Taiwan University Hospital
Organization:
National Taiwan University Hospital
Study Overview
Official Title:
The Utility of Cell-free DNA Methylation Markers for the Response Prediction of Systemic Treatment for Hepatocellular Carcinoma
Status:
UNKNOWN
Status Verified Date:
2022-10
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The subjects of this study were patients with liver cancer diagnosed by physicians according to AASLD clinical criteria or pathological biopsy
Those who plan to receive systemic drug treatment for liver cancer in National Taiwan University Hospital include Nexavar Lenvatinib Avastin Tecentriq Strivarga Cabometyx Cyramza Nivolunab Pembrolizumab and Yervoy Weak and uncooperative patients were excluded from blood tests which were performed with full informed consent for relevant tumor markers AFP PIVKA-II and methylation analysis The data are then counted and compared
Those who plan to receive systemic drug treatment for liver cancer in National Taiwan University Hospital include Nexavar Lenvatinib Avastin Tecentriq Strivarga Cabometyx Cyramza Nivolunab Pembrolizumab and Yervoy Weak and uncooperative patients were excluded from blood tests which were performed with full informed consent for relevant tumor markers AFP PIVKA-II and methylation analysis The data are then counted and compared
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None